Metabolomics: A Tool for Personalizing Medicine?

• van der Greef J : Systems biology, connectivity and the future of medicine.Syst. Biol.152(4) , 174–178 (2005).
   Google Scholar
• Nebert DW , VesellES: Advances in pharmacogenomics and individualized drug therapy: exciting challenges that lie ahead.Eur. J. Pharmacol.500(1–3) , 267–280 (2005).
   Web of Science ®Google Scholar
• Schnackenberg LK , BegerRD: Monitoring the health to disease continuum with global metabolic profiling and systems biology.Pharmacogenomics7(7) , 1077–1086 (2006).
   PubMed Web of Science ®Google Scholar
• van der Greef J , HankemeierT, McBurney RN: Metabolomics-based systems biology and personalized medicine: moving towards n = 1 clinical trials? Pharmacogenomics7(7) , 1087–1094 (2006).
   PubMed Web of Science ®Google Scholar
• Nebert DW , Jorge-NebertL, VesellES: Pharmacogenomics and “individualized drug therapy”: high expectations and disappointing achievements.Am. J. Pharmacogenomics3(6) , 361–370 (2003).
   PubMedGoogle Scholar
• Helgadottir AA , ManolescuA, HelgasonG et al.: A variant of the gene encoding leukotriene A4 hydrolase confers ethnicity-specific risk of myocardial infarction. Nat. Genet.38(1) , 68–74 (2006).
   PubMed Web of Science ®Google Scholar
• German JB , BaumanDE, BurrinDG et al.: Metabolomics in the opening decade of the 21st century: building the roads to individual health. J. Nutr.134(10) , 2729–2732 (2004).
   PubMed Web of Science ®Google Scholar
• Fiehn O : Combining genomics, metabolome analysis, and biochemical modeling to understand metabolic networks.Comp. Funct. Genom.2(3) , 155–168 (2001).
   PubMed Web of Science ®Google Scholar
• Fiehn O : Metabolomics – the link between genotypes and phenotypes.Plant Mol. Biol.48(1–2) , 155–171 (2002).
   PubMed Web of Science ®Google Scholar
• Nicholson JK , LindonJC, HolmesE: ‘Metabonomics‘: understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data.Xenobiotica29(11) , 1181–1189 (1999).
   PubMed Web of Science ®Google Scholar
• Hall R , BealeM, FiehnO, HardyN, SumnerL, BinoR: Plant metabolomics: the missing link in functional genomics strategies.Plant Cell14(7) , 1437–1440 (2002).
   PubMedGoogle Scholar
• Griffin JL : Metabonomics: NMR spectroscopy and pattern recognition analysis of body fluids and tissues for characterisation of xenobiotic toxicity and disease diagnosis.Curr. Opin. Chem. Biol.7(5) , 648–654 (2003).
   PubMed Web of Science ®Google Scholar
• Ippolito JE , XuJ, JainS et al.: An integrated functional genomics and metabolomics approach for defining poor prognosis in human neuroendocrine cancers. Proc. Natl Acad. Sci. USA102(28) , 9901–9906 (2005).
   PubMed Web of Science ®Google Scholar
• Boros LG , BrackettDJ, HarriganGG: Metabolic biomarker and kinase drug target discovery in cancer using stable isotope-based dynamic metabolic profiling (SIDMAP).Curr. Cancer Drug Targets3(6) , 447–455 (2003).
   Web of Science ®Google Scholar
• Harrigan GG , ColcaJ, SzalmaS, BorosLG: PNU-91325 increases fatty acid synthesis from glucose and mitochondrial long chain fatty acid degradation: a comparative tracer-based metabolomics study with rosiglitazone and pioglitazone in HepG2 cells.Metabolomics2(1) , 21–29 (2006).
   PubMed Web of Science ®Google Scholar
• Maguire G , LeeP, ManheimD, BorosL: SiDMAP: a metabolomics approach to assess the effects of drug candidates on the dynamic properties of biochemical pathways.Expert Opin. Drug Discov.1(4) , 351–359 (2006).
   PubMed Web of Science ®Google Scholar
• Nicholson JK , HolmesE, WilsonID: Gut microbes, mammalian metabolism and personalized healthcare.Nat. Rev. Microbiol.3(5) , 2–8 (2005).
   PubMed Web of Science ®Google Scholar
• Lenz EM , BrightJ, WilsonID, MorganSR, NashAF: A 1H NMR-based metabonomic study of urine and plasma samples obtained from healthy human subjects.J. Pharm. Biomed. Anal.33(5) , 1103–1115 (2003).
   PubMed Web of Science ®Google Scholar
• Lenz EM , BrightJ, WilsonID et al.: Metabonomics, dietary influences and cultural differences: a 1H NMR-based study of urine samples obtained from healthy British and Swedish subjects. J. Pharm. Biomed. Anal.36(4) , 841–849 (2004).
   PubMed Web of Science ®Google Scholar
• Dumas ME , MaibaumEC, TeagueC et al.: Assessment of analytical reproducibility of 1H NMR spectroscopy based metabonomics for large-scale epidemiological research: the INTERMAP study. Anal. Chem.78(7) , 2199–2208 (2006).
   PubMed Web of Science ®Google Scholar
• Holmes E , LooRL, CloarecO et al.: Detection of urinary drug metabolite (xenometabolome) signatures in molecular epidemiology studies via statistical total correlation (NMR) spectroscopy. Anal. Chem.79(7) , 2629–2640 (2007).
   PubMed Web of Science ®Google Scholar
• Assfalg M , BertiniI, ColangiuliD et al.: Evidence of different metabolic phenotypes in humans. Proc. Natl Acad. Sci. USA105(5) , 1420–1424 (2008).
   PubMed Web of Science ®Google Scholar
• Robertson DG : Metabonomics in toxicology: a review.Toxicol. Sci.85(2) , 809–822 (2005).
   PubMed Web of Science ®Google Scholar
• Portilla D , LiS, NagothuK et al.: Metabolomic study of cisplatin-induced nephrotoxicity. Kidney Int.69(12) , 2194–2204 (2006).
   PubMed Web of Science ®Google Scholar
• Schnackenberg LK , JonesRC, Thyparambil S et al.: An integrated study of acute effects of valproic acid in the liver using metabonomics, proteomics, and transcriptomics platforms. Omics10(1) , 1–14 (2006).
   PubMed Web of Science ®Google Scholar
• Espandiari P , ZhangJ, RosenzweigB et al.: The utility of a rodent model in detecting pediatric drug-induced nephrotoxicity. Toxicol. Sci.99(2) , 637–648 (2007).
   PubMed Web of Science ®Google Scholar
• Harrigan GG , YatesLA: High-throughput screening, metabolomics and drug discovery.IDrugs9(3) , 188–192 (2006).
   PubMedGoogle Scholar
• Mortshire-Smith RJ , SkilesGJ, Lawrence JW et al.: Use of metabonomics to identify impaired fatty acid metabolism as the mechanism of a drug-induced toxicity. Chem. Res. Toxicol.17(2) , 165–173 (2004).
   PubMed Web of Science ®Google Scholar
• Ju C , UetrechtJP: Mechanism of idiosyncratic drug reactions: reactive metabolite formation, protein binding and the regulation of the immune system.Curr. Drug Metab.3(4) , 367–377 (2002).
   PubMedGoogle Scholar
• Zaccara G , FranciottaD, PeruccaE: Idiosyncratic adverse reactions to antiepileptic drugs.Epilepsia48(7) , 1223–1244 (2007).
   PubMed Web of Science ®Google Scholar
• Navarro VJ , SeniorJR: Drug-related hepatotoxicity.N. Engl. J. Med.354(7) , 731–739 (2006).
   PubMed Web of Science ®Google Scholar
• Ulrich RG : Idiosyncratic toxicity: a convergence of risk factors.Annu. Rev. Med.58 , 17–34 (2007).
   PubMed Web of Science ®Google Scholar
• Salerno RA , LeskoLJ: Pharmacogenomic data: FDA voluntary and required submission guidance.Pharmacogenomics5(5) , 503–505 (2004).
   PubMed Web of Science ®Google Scholar
• Motsinger AA , RitchieMD: Multifactor dimensionality reduction: an analysis strategy for modeling and detecting gene–gene interactions in human genetics and pharmacogenomics studies.Hum. Genomics2(5) , 318–328 (2006).
   PubMedGoogle Scholar
• Zembrzuski VM , Callegari-JacquesSM, HutzMH: Application of an African Ancestry Index as a genomic control approach in a Brazilian population.Ann. Hum. Genet.70(Pt 6) , 822–828 (2006).
   PubMed Web of Science ®Google Scholar
• Bauchet M , McEvoyLN, PearsonEE et al.: Measuring European population stratification with microarray genotype data. Am. J. Hum. Genet.80(5) , 948–956 (2007).
   PubMed Web of Science ®Google Scholar
• Dixit R , BoelsterliUA: Healthy animals and animal models of human disease(s) in safety assessment of human pharmaceuticals, including therapeutic antibodies.Drug Discov. Today12(7–8) , 336–342 (2007).
   PubMed Web of Science ®Google Scholar
• Greaves P , WilliamsA, EveM: First dose of potential new medicines to humans: how animals help.Nat. Rev. Drug Discov.3(3) , 226–236 (2004).
   PubMed Web of Science ®Google Scholar
• Larson AM , PolsonJ, FontanaRJ et al.: Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology42(6) , 1364–1372 (2005).
   PubMed Web of Science ®Google Scholar
• Espandiari P , ZhangJ, RosenzweigBA et al.: The utility of a rodent model in detecting drug-induced nephrotoxicity. Toxicol. Sci.99(2) , 637–648 (2007).
   PubMed Web of Science ®Google Scholar
• Clayton TA , LindonJC, CloarecO et al.: Pharmaco–metabonomic phenotyping and personalized drug treatment. Nature440(7087) , 1073–1077 (2006).
   PubMed Web of Science ®Google Scholar
• Schnackenberg LK , DraganYP, ReilyMD, RobertsonDG, BegerRD: Evaluation of NMR spectral data of urine in conjunction with measured clinical chemistry and histopathology parameters to assess the effects of liver and kidney toxicants.Metabolomics3(2) , 87–100 (2007).
   Web of Science ®Google Scholar
• Whitcomb DC , BlockGD: Association of acetaminophen hepatotoxicity with fasting and ethanol use.JAMA272(23) , 1845–1850 (1994).
   PubMed Web of Science ®Google Scholar
• Schwarz UI : Clinical relevance of genetic polymorphisms in the human CYP2C9 gene.Eur. J. Clin. Invest.33(Suppl. 2) , 23–30 (2003).
   PubMed Web of Science ®Google Scholar
• Lindh JD , LundgrenS, HolmL, Alfredsson L, Rane A: Several-fold increase in risk of overanticoagulation by CYP2C9 mutations. Clin. Pharmacol. Ther.78(5) , 540–550 (2005).
   PubMed Web of Science ®Google Scholar
• Murray M : Role of CYP pharmacogenetics and drug–drug interactions in the efficacy and safety of atypical and other antipsychotic agents.J. Pharm. Pharmacol.58(7) , 871–885 (2006).
   PubMed Web of Science ®Google Scholar
• Stamer UM , MusshoffF, KobilaryM, MadeaB, HoeftA, StuberF: Concentrations of tramadol and O-desmethyltramadol enantiomers in different CYP2D6 genotypes.Clin. Pharmacol. Ther.82(1) , 41–47 (2007).
   PubMed Web of Science ®Google Scholar
• Tornio A , NiemiM, NeuvonenPJ, BackmanJT: Trimethoprim and the CYP2C8*3 allele have opposite effects on the pharmacokinetics of pioglitazone.Drug Metab. Dispos.36(1) , 73–80 (2007).
   PubMed Web of Science ®Google Scholar
• Blumberg J : Nutritional needs of seniors.J. Am. Coll. Nutr.16(6) , 517–523 (1997).
   PubMed Web of Science ®Google Scholar
• Drewnowski A , Warren-MearsVA: Does aging change nutrition requirements?J. Nutr. Health Aging5(2) , 70–74 (2001).
   PubMedGoogle Scholar
• Kennedy ET : Evidence for nutritional benefits in prolonging wellness.Am. J. Clin. Nutr.83(2) , S410–S414 (2006).
   PubMed Web of Science ®Google Scholar
• McKevith B : Diet and healthy ageing.J. Br. Menopause Soc.11(4) , 121–125 (2005).
   PubMedGoogle Scholar
• Baker H : Nutrition in the elderly: an overview.Geriatrics62(7) , 28–31 (2007).
   PubMed Web of Science ®Google Scholar
• Rivlin RS : Keeping the young-elderly healthy: is it too late to improve our health through nutrition?Am. J. Clin. Nutr.86(5) , S1572–S1576 (2007).
   Web of Science ®Google Scholar
• Whitfield PD , GermanAJ, NoblePJ: Metabolomics: an emerging post-genomic tool for nutrition.Br. J. Nutr.92(4) , 549–555 (2004).
   PubMed Web of Science ®Google Scholar
• Gibney MJ , WalshM, BrennanL, Roche HM, German AJ, van Ommen B: Metabolomics in human nutrition: opportunities and challenges. Am. J. Clin. Nutr.82(3) , 497–503 (2005).
   PubMed Web of Science ®Google Scholar
• Kaput J , OrdovasJM, FergusonL et al.: The case for strategic international alliances to harness nutritional genomics for public and personal health. Br. J. Nutr.94(5) , 623–632 (2005).
   PubMed Web of Science ®Google Scholar
• Zeisel SH , FreakeHC, BaumanDE et al.: The nutritional phenotype in the age of metabolomics. J. Nutr.135(7) , 1613–1616 (2005).
   PubMed Web of Science ®Google Scholar
• Kussmann M , RaymondF, AffolterM: Omics-driven biomarker discovery in nutrition and health.J. Biotechnol.124(4) , 758–787 (2006).
   PubMed Web of Science ®Google Scholar
• Trujillo E , DavisC, MilnerJ: Nutrigenomics, proteomics, metabolomics, and the practice of dietetics.J. Am. Diet Assoc.106(3) , 403–413 (2006).
   PubMed Web of Science ®Google Scholar
• Veech RL , EgglestonLV, KrebsHA: The redox state of free nicotinamide–adenine dinucleotide phosphate in the cytoplasm of rat liver.Biochem. J.115(4) , 609–619 (1969).
   PubMed Web of Science ®Google Scholar
• Djuric Z , LewisSM, LuMH, MayhughM, TangN, HartRW: Effect of varying dietary fat levels on rat growth and oxidative DNA damage.Nutr. Cancer39(2) , 214–219 (2001).
   PubMed Web of Science ®Google Scholar
• Duffy PH , SengJE, LewisSM et al.: The effects of different levels of dietary restriction on aging and survival in the Sprague–Dawley rat: implications for chronic studies. Aging13(4) , 263–272 (2001).
   PubMedGoogle Scholar
• Harris RZ , JangGR, TsunodaS: Dietary effects on drug metabolism and transport.Clin. Pharmacokinet.42(13) , 1071–1088 (2003).
   PubMed Web of Science ®Google Scholar
• Milner JA : Molecular targets for bioactive food components.J. Nutr.134(9) , S2492–S2498 (2004).
   Web of Science ®Google Scholar
• Ross SA : Nutritional genomic approaches to cancer prevention research.Exp. Oncol.29(4) , 250–256 (2007).
   PubMedGoogle Scholar
• Arayne MS , SultanaN, BibiZ: Grape fruit juice–drug interactions.Pak. J. Pharm. Sci.18(4) , 45–57 (2005).
   PubMedGoogle Scholar
• Sica DA : Interaction of grapefruit juice and calcium channel blockers.Am. J. Hypertens.19(7) , 768–773 (2006).
   PubMed Web of Science ®Google Scholar
• Saito M , Hirata-KoizumiM, Matsumoto M, Urano T, Hasegawa R: Undesirable effects of citrus juice on the pharmacokinetics of drugs: focus on recent studies. Drug Saf.28(8) , 677–694 (2005).
   PubMed Web of Science ®Google Scholar
• Bailey DG , DresserGK, KreeftJH, Munoz C, Freeman DJ, Bend JR: Grapefruit–felodipine interaction: effect of unprocessed fruit and probable active ingredients. Clin. Pharmacol. Ther.68(5) , 468–477 (2000).
   PubMed Web of Science ®Google Scholar
• Bailey DG , DresserGK, BendJR: Bergamottin, lime juice, and red wine as inhibitors of cytochrome P450 3A4 activity: comparison with grapefruit juice.Clin. Pharmacol. Ther.73(6) , 529–537 (2003).
   PubMed Web of Science ®Google Scholar
• Moon YJ , WangX, MorrisME: Dietary flavonoids: effects on xenobiotic and carcinogen metabolism.Toxicol.In Vitro20(2) , 187–210 (2006).
   Web of Science ®Google Scholar
• Smith DA , AbelSM, HylandR, JonesBC: Human cytochrome P450s: selectivity and measurement in vivo.Xenobiotica28(12) , 1095–1128 (1998).
   PubMed Web of Science ®Google Scholar
• Walter-Sack I , KlotzU: Influence of diet and nutritional status on drug metabolism.Clin. Pharmacokinet.31(1) , 47–64 (1996).
   PubMed Web of Science ®Google Scholar
• Murray M , PetrovicN: Cytochrome P450: decision-making tools for personalized therapeutics.Curr. Opin. Mol. Ther.8(6) , 480–486 (2006).
   PubMedGoogle Scholar
• Murray M : Altered CYP expression and function in response to dietary factors: potential roles in disease pathogenesis.Curr. Drug Metab.7(1) , 67–81 (2006).
   PubMed Web of Science ®Google Scholar
• Nekvindova J , AnzenbacherP: Interactions of food and dietary supplements with drug metabolising cytochrome P450 enzymes.Ceska Slov. Farm.56(4) , 165–173 (2007).
   PubMedGoogle Scholar
• Kaput J , PerlinaA, HatipogluB, BartholomewA, NikolskyY: Nutrigenomics: concepts and applications to pharmacogenomics and clinical medicine.Pharmacogenomics8(4) , 369–390 (2007).
   PubMed Web of Science ®Google Scholar
• Suttie JW : Warfarin and vitamin K.Clin. Cardiol.13(4 Suppl. 6) , VI16–VI18 (1990).
   PubMed Web of Science ®Google Scholar
• Booth SL , CenturelliMA: Vitamin K: a practical guide to the dietary management of patients on warfarin.Nutr. Rev.57(I9) , 288–296 (1999).
   PubMed Web of Science ®Google Scholar
• Merli GJ , FinkJ: Vitamin K and thrombosis.Vitam. Horm.78 , 265–279 (2008).
   PubMed Web of Science ®Google Scholar
• Sellers EM , HollowayMR: Drug kinetics and alcohol ingestion.Clin. Pharmacokinet.3(6) , 440–452 (1978).
   PubMed Web of Science ®Google Scholar
• Weathermon R , CrabbDW: Alcohol and medication interactions.Alcohol Res. Health23(1) , 40–54 (1999).
   PubMedGoogle Scholar
• Izzo AA , ErnstE: Interactions between herbal medicines and prescribed drugs: a systematic review.Drugs61(15) , 2163–2175 (2001).
   PubMed Web of Science ®Google Scholar
• Hu Z , YangX, HoPC et al.: Herb–drug interactions: a literature review. Drugs65(9) , 1239–1282 (2005).
   PubMed Web of Science ®Google Scholar
• Shalansky S , LyndL, RichardsonK, IngaszewskiA, KerrC: Risk of warfarin-related bleeding events and supratherapeutic international normalized ratios associated with complementary and alternative medicine: a longitudinal analysis.Pharmacotherapy27(9) , 1237–1247 (2007).
   PubMed Web of Science ®Google Scholar
• Hollman PC , KatanMB: Absorption, metabolism and health effects of dietary flavonoids in man.Biomed. Pharmacother.51(8) , 305–310 (1997).
   PubMed Web of Science ®Google Scholar
• Shih H , PickwellGV, QuattrochiLC: Differential effects of flavonoid compounds on tumor promoter-induced activation of the human CYP1A2 enhancer.Arch. Biochem. Biophys.373(1) , 287–294 (2000).
   PubMed Web of Science ®Google Scholar
• Waters E , WangJH, RedmondHP, Wu QD, Kay E, Bouchier-Hayes D: Role of taurine in preventing acetaminophen-induced hepatic injury in the rat. Am. J. Physiol. Gastrointest. Liver Physiol.280(6) , G1274–G1279 (2001).
   PubMed Web of Science ®Google Scholar
• Han D , HanawaN, SaberiB, KaplowitzN: Mechanisms of liver injury. III. Role of glutathione redox status in liver injury.Am. J. Physiol. Gastrointest. Liver Physiol.291(1) , G1–G7 (2006).
   PubMed Web of Science ®Google Scholar
• Lee WM : Acetaminophen and the U.S. Acute Liver Failure Study Group: lowering the risks of hepatic failure.Hepatology40(1) , 6–9 (2004).
   PubMed Web of Science ®Google Scholar
• Amar PJ , SchiffER: Acetaminophen safety and hepatotoxicity – where do we go from here?Expert Opin. Drug Saf.6(4) , 341–355 (2007).
   PubMed Web of Science ®Google Scholar
• Bessems JG , VermeulenNP: Paracetamol (acetaminophen)-induced toxicity: molecular and biochemical mechanisms, analogues, and protective approaches.Crit. Rev. Toxicol.31(1) , 55–138 (2001).
   PubMed Web of Science ®Google Scholar
• Moffit JS , Koza-TaylorPH, HollandRD et al.: Differential gene expression in mouse liver associated with the hepatoprotective effect of clofibrate. Toxicol. Appl. Pharmacol.222(2) , 169–179 (2007).
   PubMed Web of Science ®Google Scholar
• Sies H , StahlW, SundquistAR: Antioxidant functions of vitamins. Vitamins E and C, β-carotene, and other carotenoids.Ann. NY Acad. Sci.669 , 7–20 (1992).
   PubMed Web of Science ®Google Scholar
• Arrigoni O , de Tullio MC: Ascorbic acid: much more than just an antioxidant. Biochem. Biophys. Acta1569(1–3) , 1–9 (2002).
   PubMed Web of Science ®Google Scholar
• Lappe JM , Travers-GustafsonD, Davies KM, Recker RR, Heaney RP: Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am. J. Clin. Nutr.85(6) , 1586–1591 (2007).
   PubMed Web of Science ®Google Scholar
• Fariss MW , ZhangJG: Vitamin E therapy in Parkinson‘s disease.Toxicology189(1–2) , 129–146 (2003).
   PubMed Web of Science ®Google Scholar
• Salganik RI : The benefits and hazards of antioxidants: controlling apoptosis and other protective mechanisms in cancer patients and the human population.J. Am. Coll. Nutr.20(Suppl. 5) , S464–S472 (2001).
   PubMed Web of Science ®Google Scholar
• Leonetti C , BiroccioA, GabelliniC et al.: α-tocopherol protects against cisplatin-induced toxicity without interfering with antitumor efficacy. Int. J. Cancer104(2) , 243–250 (2003).
   PubMed Web of Science ®Google Scholar
• Ali BH , Al Moundhri MS: Agents ameliorating or augmenting the nephrotoxicity of cisplatin and other platinum compounds: a review of some recent research. Food Chem. Toxicol.44(8) , 1173–1183 (2006).
   PubMed Web of Science ®Google Scholar
• Ajith TA , UshaS, NivithaV: Ascorbic acid and α-tocopherol protect anticancer drug cisplatin induced nephrotoxicity in mice: a comparative study.Clin. Chim. Acta375(1–2) , 82–86 (2007).
   PubMed Web of Science ®Google Scholar
• Nebert DW , VesellES: Can personalized drug therapy be achieved? A closer look at pharmaco-metabonomics.Trends Pharmacol. Sci.27(11) , 580–586 (2006).
   PubMed Web of Science ®Google Scholar
• Goodsaid FM , FruehFW: Biomarker qualification pilot process at the US Food and Drug Administration.AAPS J.9(1) , E105–E108 (2007).
   PubMed Web of Science ®Google Scholar
• Goodsaid FM , FruehFW, MattesW: Strategic paths for biomarker qualification.Toxicology245(3) , 219–223 (2008).
   PubMed Web of Science ®Google Scholar

Websites

• Guidance for Industry Pharmacogenomic Data Submissions www.fda.gov/CBER/gdlns/pharmdtasub.pdf
   Google Scholar
• US FDA Critical Path Initiative www.fda.gov/oc/initiatives/criticalpath
   Google Scholar